BioSpace News Archive

Antibe Therapeutics Inc., a leader in developing safer, non-addictive therapeutics for pain and inflammation, is pleased to provide a corporate update in conjunction with the filing of its financial and operating results for the fiscal quarter ended September 30, 2019.

Liminal BioSciences Inc. acknowledges the press release issued by the Autorité des Marchés Financiers in which the AMF announced that after a thorough investigation, the AMF has determined that no violation or breach of securities regulation occurred in connection with the refinancing transactions completed by the Company in April 2019.

Hutchison China MediTech Limited announces that Elunate®, its national class 1 targeted anticancer drug for the treatment of patients with advanced colorectal cancer, has been included in the updated National Reimbursement Drug List released by China’s National Healthcare Security Administration.

Funds will advance development of ViGeneron’s next-generation ophthalmic gene therapy pipeline and vector platforms

Data show patients had a 50% reduction in risk of recurrence compared to treatment with Herceptin® (trastuzumab) after surgery2

Genetron Health, a China-based precision oncology company that covers full-cycle cancer care, has obtained regulatory approval in China to launch its GENETRON S5 for clinical use.

Pharmaron Beijing Co., Ltd. announced that 117 million H-shares are listed on the Main Board of The Stock Exchange of Hong Kong.

Ascletis Pharma Inc. announces that Ascletis XinNuo Medicine Co.,Ltd., a wholly-owned subsidiary of Ascletis, has recently obtained the Pharmaceutical Trade License and GSP Certificate issued by ZheJiang Medical Products Administration.

MedMira Inc., reported on its financial results for the financial year ended July 31, 2019.